Trial Profile
Testing the Ability of JNJ(Janssen and Janssen)18038683, a Selective Serotonin (5-HT)7 Antagonist, to Improve Cognition and Reduce Residual Depressive Symptoms in Stable Bipolar Patients (18038683BCD2001)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2023
Price :
$35
*
At a glance
- Drugs JNJ 18038683 (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 18 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 18 Jan 2022 Status changed from recruiting to active, no longer recruiting.